Nicole LaBrosse
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
-
Start not stated–2026-03-30
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Halozyme Therapeutics, Inc. (HALO) | Senior Vice President, Chief Financial Officer | $604,188 | $4,578,814 |
| 2024 | Halozyme Therapeutics, Inc. (HALO) | Senior Vice President, Chief Financial Officer | $568,188 | $4,218,276 |
| 2023 | Halozyme Therapeutics, Inc. (HALO) | Senior Vice President, Chief Financial Officer | $546,188 | $3,849,419 |
| 2022 | Halozyme Therapeutics, Inc. (HALO) | Senior Vice President, Chief Financial Officer | $467,836 | $2,683,103 |
Recent activity
Earnings-call appearances and filed executive appointments or departures, newest first.